Runben Biotechnology Co Ltd Ordinary Shares - Class A
Runben Biotechnology Co., Ltd. engages in the research, production, and sale of mosquito repellent products, baby care products, and essential oil products. The company sells its products through online channels. Runben Biotechnology Co., Ltd. was founded in 1993 and is based in Guangzhou, China.Runben Biotechnology Co., Ltd. operates as a subsidiary of Guangzhou Zhuofan Investment Holding Co., L… Read more
Runben Biotechnology Co Ltd Ordinary Shares - Class A (603193) - Total Assets
Latest total assets as of September 2025: CN¥2.31 Billion CNY
Based on the latest financial reports, Runben Biotechnology Co Ltd Ordinary Shares - Class A (603193) holds total assets worth CN¥2.31 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Runben Biotechnology Co Ltd Ordinary Shares - Class A - Total Assets Trend (2019–2024)
This chart illustrates how Runben Biotechnology Co Ltd Ordinary Shares - Class A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Runben Biotechnology Co Ltd Ordinary Shares - Class A - Asset Composition Analysis
Current Asset Composition (December 2024)
Runben Biotechnology Co Ltd Ordinary Shares - Class A's total assets of CN¥2.31 Billion consist of 71.9% current assets and 28.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 4.8% |
| Accounts Receivable | CN¥18.20 Million | 0.8% |
| Inventory | CN¥118.57 Million | 5.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥54.54 Million | 2.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Runben Biotechnology Co Ltd Ordinary Shares - Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Runben Biotechnology Co Ltd Ordinary Shares - Class A's current assets represent 71.9% of total assets in 2024, an increase from 44.9% in 2019.
- Cash Position: Cash and equivalents constituted 4.8% of total assets in 2024, down from 18.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 12.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 5.3% of total assets.
Runben Biotechnology Co Ltd Ordinary Shares - Class A Competitors by Total Assets
Key competitors of Runben Biotechnology Co Ltd Ordinary Shares - Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Lonkey Industrial Co Ltd Guangzhou
SHE:000523
|
China | CN¥3.66 Billion |
|
Taiyen Biotech Co Ltd
TW:1737
|
Taiwan | NT$8.26 Billion |
|
Tianjin Yiyi Hygiene Products Co Ltd
SHE:001206
|
China | CN¥2.20 Billion |
|
Hunan Resun Co Ltd
SHE:001218
|
China | CN¥3.08 Billion |
|
Dencare (Chongqing) Oral Care Co. Ltd. A
SHE:001328
|
China | CN¥1.90 Billion |
|
Qingdao Kingking Applied Chemistry Co Ltd
SHE:002094
|
China | CN¥3.19 Billion |
|
C&S Paper Co Ltd
SHE:002511
|
China | CN¥9.17 Billion |
|
Anhui Deli Household Glass Co Ltd
SHE:002571
|
China | CN¥3.08 Billion |
Runben Biotechnology Co Ltd Ordinary Shares - Class A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Runben Biotechnology Co Ltd Ordinary Shares - Class A generates 0.59x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Runben Biotechnology Co Ltd Ordinary Shares - Class A generates $ 13.52 in net profit.
Runben Biotechnology Co Ltd Ordinary Shares - Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.51 | 10.60 | 3.35 |
| Quick Ratio | 11.47 | 9.90 | 2.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.49 Billion | CN¥ 1.68 Billion | CN¥ 339.47 Million |
Runben Biotechnology Co Ltd Ordinary Shares - Class A - Advanced Valuation Insights
This section examines the relationship between Runben Biotechnology Co Ltd Ordinary Shares - Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.33 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | 9.9% |
| Total Assets | CN¥2.22 Billion |
| Market Capitalization | $243.86 Million USD |
Valuation Analysis
Below Book Valuation: The market values Runben Biotechnology Co Ltd Ordinary Shares - Class A's assets below their book value (0.11 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Runben Biotechnology Co Ltd Ordinary Shares - Class A's assets grew by 9.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Runben Biotechnology Co Ltd Ordinary Shares - Class A (2019–2024)
The table below shows the annual total assets of Runben Biotechnology Co Ltd Ordinary Shares - Class A from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.22 Billion | +9.93% |
| 2023-12-31 | CN¥2.02 Billion | +144.59% |
| 2022-12-31 | CN¥825.42 Million | +27.71% |
| 2021-12-31 | CN¥646.34 Million | +133.79% |
| 2020-12-31 | CN¥276.47 Million | +68.14% |
| 2019-12-31 | CN¥164.43 Million | -- |